University of California, Los Angeles Neuro-Oncology : Clinical Trials: Open Enrollment

Contact Us \| Directions \| Referring a Patient
A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis, cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.

Home > Patient Care > Clinical Trials: Open Enrollment

Clinical Trials: Open Enrollment

The following is a listing of all trials currently enrolling brain tumor patients at UCLA.

World Class Oncology

First Steps of Treatment

What to Bring to Your First Clinic Visit

Neuro-Oncology Clinic

Personalized Medicine using Molecular Diagnostics

Brain Mapping with Functional MRI

Finding a Clinical Trial

Referring A Patient

Telephone Numbers, Visiting Hours

Travel Directions

International Patients

What clinical trials are available at UCLA Neuro-Oncology?

Choosing to participate in a clinical trial is an important, personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521

Study Agent	IRB ID	Trial:Details
NONE	03-04-057	(NABTC 01-07) A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas. [R6 dated 8May07] :
Sorafenib in combination w/OSI-774 or R115777 or CCI-779	06-04-030	[NABTC 05-02] Ph I/II Studies of BAY 43-9006 (Sorafenib) in Combination with OSI-774, R115777 or CCI-779 in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma. :
TARCEVA (erlotinib HCl)	06-04-104	(OSI3781s) Ph I/II, Dual-Center, Open-Label Trial of the Safet and Efficacy of Tarceva TM Plus Sirolimus in Patients with Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics. [version24Mar06] :
Vorinostat	05-12-061	(NABTC 04-03) A Phase I Study of Vorinostat (SAHA) in Combination with Temozolomide in Patients with Malignant Gliomas. [R6 dated 15Feb07] :
Vorinostat in combination with Temozolomide	05-12-061	(NABTC 04-03) Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas. [R3 dated 12Jun06] :
XL184	09-04-050-01C	XL184-201: Ph 2 Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse. (Protocol R5, ICF 01A) :
XL765 and Temozolomide	08-01-061	[XL765-002 Exelixis] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Glioma. :
XL765 and Temozolomide	08-01-061	[XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas. (R1 dated 15Apr08):

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, Provider^IQ) 1998-2010 SiliconMED North America

Provider^IQ is a registered trademark of SiliconMED North America and used by permission.

[Content Published:3/10/2010 7:11:48 AM PST]